Investors Purchase High Volume of Call Options on Heron Therapeutics (HRTX)
Heron Therapeutics, Inc. (NASDAQ:HRTX) was the recipient of unusually large options trading on Tuesday. Investors acquired 2,953 call options on the company. This is an increase of approximately 781% compared to the typical daily volume of 335 call options.
A number of equities analysts have weighed in on the company. Cowen reissued a “buy” rating and set a $40.00 price target on shares of Heron Therapeutics in a research report on Wednesday. ValuEngine raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 30th. Zacks Investment Research raised Heron Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a research report on Wednesday, November 22nd. Noble Financial reissued a “buy” rating on shares of Heron Therapeutics in a research report on Sunday, November 12th. Finally, Oppenheimer reissued a “buy” rating and set a $27.00 price target on shares of Heron Therapeutics in a research report on Friday, November 10th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Heron Therapeutics has an average rating of “Buy” and a consensus price target of $28.73.
Large investors have recently modified their holdings of the company. Legal & General Group Plc boosted its holdings in shares of Heron Therapeutics by 13.9% during the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 1,098 shares during the period. Quantbot Technologies LP boosted its holdings in shares of Heron Therapeutics by 2,619.6% during the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock worth $172,000 after acquiring an additional 12,024 shares during the period. Trexquant Investment LP bought a new stake in shares of Heron Therapeutics during the third quarter worth approximately $206,000. Jane Street Group LLC bought a new stake in shares of Heron Therapeutics during the third quarter worth approximately $223,000. Finally, HighTower Advisors LLC boosted its holdings in shares of Heron Therapeutics by 11.4% during the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 1,700 shares during the period.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.10. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. The company had revenue of $8.57 million during the quarter, compared to analysts’ expectations of $8.12 million. sell-side analysts anticipate that Heron Therapeutics will post -3.42 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/08/investors-purchase-high-volume-of-call-options-on-heron-therapeutics-hrtx.html.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.